{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:55:16Z","timestamp":1791266116034,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00228-026-04192-7","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:30:19Z","timestamp":1791264619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic model of high-dose methotrexate in Malaysian adults with hematological malignancies"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6296-4090","authenticated-orcid":false,"given":"Tuan Fauziah","family":"Tuan-Roslli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8889-5579","authenticated-orcid":false,"given":"Mohd H","family":"Abdul-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0592-0645","authenticated-orcid":false,"given":"Mohd","family":"Makmor-Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-4213","authenticated-orcid":false,"given":"Noraida","family":"Mohamed Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6243-6975","authenticated-orcid":false,"given":"Shamin","family":"Mohd Saffian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"6","key":"4192_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1067\/mcp.2000.106932","volume":"67","author":"E Zylber-Katz","year":"2000","unstructured":"Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T (2000) Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin Pharmacol Ther 67(6):631\u2013641. https:\/\/doi.org\/10.1067\/mcp.2000.106932","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"4192_CR2","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood.V126.23.3956.3956","volume":"126","author":"T Lin","year":"2015","unstructured":"Lin T, Li X, Liu T, Huang H, Hong H, Guo C et al (2015) A prospective, self-controlled and randomized study about the optimal timing of leucovorin rescue after high dose methotrexate management. Blood 126(23):3956","journal-title":"Blood"},{"issue":"12","key":"4192_CR3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 21(12):1471\u20131482. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"issue":"12","key":"4192_CR4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.1987.5.12.2017","volume":"5","author":"SP Ackland","year":"1987","unstructured":"Ackland SP, Schilsky RL (1987) High-dose methotrexate: a critical reappraisal. J Clin Oncol 5(12):2017\u20132031. https:\/\/doi.org\/10.1200\/jco.1987.5.12.2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"4192_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/pbc.24081","volume":"59","author":"G Kapoor","year":"2012","unstructured":"Kapoor G, Sinha R, Abedin S (2012) Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country. Pediatr Blood Cancer 59(3):448\u2013453. https:\/\/doi.org\/10.1002\/pbc.24081","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"4192_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s43046-025-00324-9","volume":"37","author":"H Ehab Barakat","year":"2025","unstructured":"Ehab Barakat H, Ashraf El bahy K, Victor Labib S, Zakaria Aldesouky Y, Ayman Ismail A, El Sayed Mohamed M et al (2025) Comprehensive evaluation of high dose methotrexate therapy: a retrospective observational trial. J Egypt Natl Cancer Inst 37(1):69. https:\/\/doi.org\/10.1186\/s43046-025-00324-9","journal-title":"J Egypt Natl Cancer Inst"},{"key":"4192_CR7","doi-asserted-by":"publisher","first-page":"1660937","DOI":"10.3389\/fonc.2025.1660937","volume":"15","author":"M Al Manasour","year":"2025","unstructured":"Al Manasour M, Absi A, Alhuraiji A, Khanani MF, Mheidly K, Elsaid M et al (2025) Consensus on managing delayed methotrexate elimination in high-dose therapy: insights from the Middle East. Front Oncol 15:1660937. https:\/\/doi.org\/10.3389\/fonc.2025.1660937","journal-title":"Front Oncol"},{"issue":"10","key":"4192_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00432-024-05945-6","volume":"150","author":"SS Bielack","year":"2024","unstructured":"Bielack SS, Soussain C, Fox CP, Houillier C, Murciano T, Osborne W et al (2024) A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. J Cancer Res Clin Oncol 150(10):441. https:\/\/doi.org\/10.1007\/s00432-024-05945-6","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4192_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey LB, Balis FM, O\u2019Brien MM, Schmiegelow K, Pauley JL, Bleyer A et al (2018) Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 23(1):52\u201361. https:\/\/doi.org\/10.1634\/theoncologist.2017-0243","journal-title":"Oncologist"},{"issue":"4","key":"4192_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/FTD.0000000000001401","volume":"48","author":"T Fauziah","year":"2025","unstructured":"Fauziah T, Goh AS, Mohamed Shah N, Makmor-Bakry M, Mohd Saffian S (2025) Delayed Elimination Concentrations of High-Dose Methotrexate in Adults With Hematological Malignancies: To Standardize or Not? A Scoping Review. Ther Drug Monit 48(4):432\u2013442. https:\/\/doi.org\/10.1097\/FTD.0000000000001401","journal-title":"Ther Drug Monit"},{"key":"4192_CR11","doi-asserted-by":"publisher","first-page":"106416","DOI":"10.1016\/j.ejps.2023.106416","volume":"186","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wang C, Chen Y, Wang X, Jiao Z, Wang Z (2023) External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients. Eur J Pharm Sci 186:106416. https:\/\/doi.org\/10.1016\/j.ejps.2023.106416","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"4192_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/jcph.2392","volume":"64","author":"S Chen","year":"2024","unstructured":"Chen S, Huang L, Huang W, Zheng Y, Shen L, Liu M et al (2024) External Evaluation of Population Pharmacokinetic Models for High-Dose Methotrexate in Adult Patients with Hematological Tumors. J Clin Pharmacol 64(4):437\u2013448. https:\/\/doi.org\/10.1002\/jcph.2392","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4192_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000543181","volume":"70","author":"N Maximova","year":"2025","unstructured":"Maximova N, Calabr\u00f2 PF, Cangialosi A, Di Paolo A, Maximova N (2025) Therapeutic Drug Monitoring, Population Pharmacokinetics Models, and External Validation of High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia. Chemotherapy 70(3):109\u2013118. https:\/\/doi.org\/10.1159\/000543181","journal-title":"Chemotherapy"},{"issue":"4S","key":"4192_CR14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease","year":"2024","unstructured":"Kidney Disease (2024) Improving Global Outcomes CKDWG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105(4S):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"9","key":"4192_CR15","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.xkme.2025.101068","volume":"7","author":"Y Shen","year":"2025","unstructured":"Shen Y, Cui J, Yang R, Shao W, Yang J, Wang B et al (2025) Comparison of the 2021 and 2012 CKD-EPI eGFR Equations With the 2009 CKD-EPI eGFR Equation in a Chinese Population. Kidney Med 7(9):101068. https:\/\/doi.org\/10.1016\/j.xkme.2025.101068","journal-title":"Kidney Med"},{"key":"4192_CR16","unstructured":"DavidC (2023) Body surface area (Mosteller). https:\/\/www.vcalc.com. Accessed Nov 2025"},{"key":"4192_CR17","doi-asserted-by":"crossref","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5)","DOI":"10.1023\/A:1012299115260"},{"key":"4192_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jclinepi.2022.08.016","volume":"151","author":"MW Heymans","year":"2022","unstructured":"Heymans MW, Twisk JWR (2022) Handling missing data in clinical research. J Clin Epidemiol 151:185\u2013188. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.08.016","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"4192_CR19","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/psp4.70015","volume":"14","author":"M Wijk","year":"2025","unstructured":"Wijk M, Wasmann RE, Jacobson KR, Svensson EM, Denti P (2025) A pragmatic approach to handling censored data below the lower limit of quantification in pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 14(6):1042\u20131049. https:\/\/doi.org\/10.1002\/psp4.70015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"4192_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","volume":"84","author":"S Kawakatsu","year":"2019","unstructured":"Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ et al (2019) Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol 84(6):1339\u20131348. https:\/\/doi.org\/10.1007\/s00280-019-03966-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4192_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13318-016-0338-1","volume":"42","author":"A Nader","year":"2017","unstructured":"Nader A, Zahran N, Alshammaa A, Altaweel H, Kassem N, Wilby KJ (2017) Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters. Eur J Drug Metab Pharmacokinet 42(2):221\u2013228. https:\/\/doi.org\/10.1007\/s13318-016-0338-1","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"4192_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40262-024-01452-6","volume":"64","author":"A Yin","year":"2025","unstructured":"Yin A, de Groot FA, Guchelaar HJ, Nijland M, Doorduijn JK, Touw DJ et al (2025) Population Pharmacokinetic and Toxicity Analysis of High-Dose Methotrexate in Patients with Central Nervous System Lymphoma. Clin Pharmacokinet 64(1):79\u201391. https:\/\/doi.org\/10.1007\/s40262-024-01452-6","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4192_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s00280-006-0202-0","volume":"58","author":"DW Faltaos","year":"2006","unstructured":"Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C et al (2006) Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 58(5):626\u2013633. https:\/\/doi.org\/10.1007\/s00280-006-0202-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4192_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bcp.15969","volume":"90","author":"YS Jung","year":"2024","unstructured":"Jung YS, Son M, Lee SG, Chong JW, Kim SJ, Jang JE et al (2024) A population pharmacokinetic model of methotrexate in Korean patients with haematologic malignancy. Br J Clin Pharmacol 90(3):849\u2013862. https:\/\/doi.org\/10.1111\/bcp.15969","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4192_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2710.2008.00966.x","volume":"33","author":"K Fukuhara","year":"2008","unstructured":"Fukuhara K, Ikawa K, Morikawa N, Kumagai K (2008) Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J Clin Pharm Ther 33(6):677\u2013684. https:\/\/doi.org\/10.1111\/j.1365-2710.2008.00966.x","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"4192_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2125.2011.04084.x","volume":"73","author":"M Joerger","year":"2012","unstructured":"Joerger M, Ferreri AJ, Krahenbuhl S, Schellens JH, Cerny T, Zucca E et al (2012) Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol 73(2):240\u2013247. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04084.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4192_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/0366-6999.147829","volume":"128","author":"W Zhang","year":"2015","unstructured":"Zhang W, Zhang Q, Tian X, Zhao H, Lu W, Zhen J et al (2015) Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. Chin Med J (Engl) 128(1):111\u2013118. https:\/\/doi.org\/10.4103\/0366-6999.147829","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"4192_CR28","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1002\/prp2.883","volume":"9","author":"T Isono","year":"2021","unstructured":"Isono T, Hira D, Morikochi A, Fukami T, Ueshima S, Nozaki K et al (2021) Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. Pharmacol Res Perspect 9(6):e00883. https:\/\/doi.org\/10.1002\/prp2.883","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"4192_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00280-020-04058-4","volume":"85","author":"L Yang","year":"2020","unstructured":"Yang L, Wu H, de Winter BCM, Sheng CC, Qiu HQ, Cheng Y et al (2020) Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis. Cancer Chemother Pharmacol 85(5):881\u2013897. https:\/\/doi.org\/10.1007\/s00280-020-04058-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4192_CR30","doi-asserted-by":"publisher","first-page":"1578033","DOI":"10.3389\/fphar.2025.1578033","volume":"16","author":"S Wei","year":"2025","unstructured":"Wei S, Zhang S, Wang D, Zhang D, Lu Q, Mo J et al (2025) Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. Front Pharmacol 16:1578033. https:\/\/doi.org\/10.3389\/fphar.2025.1578033","journal-title":"Front Pharmacol"},{"issue":"3","key":"4192_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40262-026-01618-4","volume":"65","author":"ZL Taylor","year":"2026","unstructured":"Taylor ZL, Barreto EF, Cole KC, Rule AD, Kashani KB, Leung N et al (2026) Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma. Clin Pharmacokinet 65(3):465\u2013477. https:\/\/doi.org\/10.1007\/s40262-026-01618-4","journal-title":"Clin Pharmacokinet"},{"key":"4192_CR32","doi-asserted-by":"publisher","unstructured":"Arshad U, Taubert M, Seeger-Nukpezah T, Ullah S, Spindeldreier KC, Jaehde U et al (2021) Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC Cancer 21(1). https:\/\/doi.org\/10.1186\/s12885-021-08443-x","DOI":"10.1186\/s12885-021-08443-x"},{"key":"4192_CR33","doi-asserted-by":"publisher","unstructured":"Gao X, Qian X-W, Zhu X-H, Yu Y, Miao H, Meng J-H et al (2021) Population pharmacokinetics of high-dose methotrexate in chinese pediatric patients with acute lymphoblastic leukemia. Front Pharmacol 12\u20132021. https:\/\/doi.org\/10.3389\/fphar.2021.701452","DOI":"10.3389\/fphar.2021.701452"},{"issue":"4","key":"4192_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/phar.2379","volume":"40","author":"MP Pai","year":"2020","unstructured":"Pai MP, Debacker KC, Derstine B, Sullivan J, Su GL, Wang SC (2020) Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma. Pharmacotherapy: J Hum Pharmacol Drug Therapy 40(4):308\u2013319. https:\/\/doi.org\/10.1002\/phar.2379","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"key":"4192_CR35","doi-asserted-by":"publisher","first-page":"817673","DOI":"10.3389\/fphar.2022.817673","volume":"13","author":"J Mao","year":"2022","unstructured":"Mao J, Li Q, Li P, Qin W, Chen B, Zhong M (2022) Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma. Front Pharmacol 13:817673. https:\/\/doi.org\/10.3389\/fphar.2022.817673","journal-title":"Front Pharmacol"},{"issue":"2","key":"4192_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0305-7372(77)80007-8","volume":"4","author":"WA Bleyer","year":"1977","unstructured":"Bleyer WA (1977) Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4(2):87\u2013101. https:\/\/doi.org\/10.1016\/s0305-7372(77)80007-8","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4192_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jpen.1451","volume":"43","author":"PB Soeters","year":"2019","unstructured":"Soeters PB, Wolfe RR, Shenkin A (2019) Hypoalbuminemia: Pathogenesis and Clinical Significance. JPEN J Parenter Enter Nutr 43(2):181\u2013193. https:\/\/doi.org\/10.1002\/jpen.1451","journal-title":"JPEN J Parenter Enter Nutr"},{"issue":"3","key":"4192_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11739-012-0802-0","volume":"7","author":"A Gatta","year":"2012","unstructured":"Gatta A, Verardo A, Bolognesi M, Hypoalbuminemia (2012) Intern Emerg Med 7(3):193\u2013199. https:\/\/doi.org\/10.1007\/s11739-012-0802-0","journal-title":"Intern Emerg Med"},{"issue":"6","key":"4192_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00280-024-04713-0","volume":"94","author":"SR Christensen","year":"2024","unstructured":"Christensen SR, Jensen CF, Heldrup J, Taylor Z, Ramsey LB, Rosth\u00f8j S (2024) Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination. Cancer Chemother Pharmacol 94(6):775\u2013785. https:\/\/doi.org\/10.1007\/s00280-024-04713-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4192_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43046-022-00122-7","volume":"34","author":"S Barakat","year":"2022","unstructured":"Barakat S, Assem H, Salama M, Mikhael N, El Chazli Y (2022) Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia? J Egypt Natl Canc Inst 34(1):17. https:\/\/doi.org\/10.1186\/s43046-022-00122-7","journal-title":"J Egypt Natl Canc Inst"},{"issue":"12","key":"4192_CR41","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00277-016-2795-7","volume":"95","author":"SN Reiss","year":"2016","unstructured":"Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Douer D (2016) Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol 95(12):2009\u20132015. https:\/\/doi.org\/10.1007\/s00277-016-2795-7","journal-title":"Ann Hematol"},{"issue":"2","key":"4192_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11(2):371\u2013380. https:\/\/doi.org\/10.1208\/s12248-009-9112-5","journal-title":"AAPS J"},{"issue":"11","key":"4192_CR43","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2217\/pgs.14.97","volume":"15","author":"S Suthandiram","year":"2014","unstructured":"Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM et al (2014) Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics 15(11):1479\u20131494. https:\/\/doi.org\/10.2217\/pgs.14.97","journal-title":"Pharmacogenomics"},{"issue":"3","key":"4192_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/08880018.2019.1705949","volume":"37","author":"RH Razali","year":"2020","unstructured":"Razali RH, Noorizhab MNF, Jamari H, James RJ, Teh KH, Ibrahim HM et al (2020) Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL). Pediatr Hematol Oncol 37(3):185\u2013197. https:\/\/doi.org\/10.1080\/08880018.2019.1705949","journal-title":"Pediatr Hematol Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04192-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:30:22Z","timestamp":1791264622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04192-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4192"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04192-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"20 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Medical Research and Ethics Committee (MREC) with National Medical Research Register (NMRR) ID-24-02410-KB8 (IIR), the Research Ethics Committee of Universiti Kebangsaan Malaysia (JEPUKM) with Jawatankuasa Etika Penyelidikan (JEP)-2024-1044, along with approval letter from the Clinical Research Center (CRC) of the participating study site. The research was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. As this was a retrospective study using routinely collected clinical data obtained from the hospital electronic system, informed consent was not obtained. Patient confidentiality was strictly maintained throughout the data collection and analysis process.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not involve any identifiable clinical photographs of patients or any identifiable patient data.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"265"}}